BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/17/2026 8:23:29 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-02-06 01:56 |
|
Peer-Review Started |
|
2026-02-06 01:57 |
|
First Decision by Editorial Office Director |
|
2026-02-14 07:58 |
|
Return for Revision |
|
2026-02-14 07:58 |
|
Revised |
|
2026-02-25 05:56 |
|
Publication Fee Transferred |
|
2026-02-26 07:43 |
|
Second Decision by Editor |
|
2026-03-27 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-27 08:39 |
|
Articles in Press |
|
2026-03-27 08:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-26 06:30 |
|
Publish the Manuscript Online |
|
2026-07-17 08:23 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Di-Xia Zhou, Shao-Wei Jiang, Chen-Guang Zhang, Bao-Jia Cai and Hai-Dong Lv |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hai-Dong Lv, Professor, Department of Gastrointestinal Cancer Surgery, Qinghai Provincial People’s Hospital, No. 2 Gonghe Road, Chengdong District, Xining 810000, Qinghai Province, China. lvhaid@126.com |
| Key Words |
Gastric cancer; Adverse reaction; Sintilimab; Oxaliplatin plus S-1 regimen; Programmed cell death protein 1 |
| Core Tip |
This real-world study systematically compared perioperative oxaliplatin plus S-1 combined with sintilimab, nab-paclitaxel plus oxaliplatin and S-1, and capecitabine plus oxaliplatin regimens in patients with advanced gastric cancer, focusing on treatment efficacy, survival outcomes, and safety. Beyond conventional survival analyses, a prognostic model was developed and validated to stratify progression-free survival risk using readily available clinicopathological and treatment response variables. The findings demonstrate that oxaliplatin plus S-1 combined with sintilimab is associated with favorable survival outcomes with manageable toxicity, and the proposed nomogram provides a practical tool for individualized risk assessment and treatment decision-making in perioperative advanced gastric cancer. |
| Publish Date |
2026-07-17 08:23 |
| Citation |
Zhou DX, Jiang SW, Zhang CG, Cai BJ, Lv HD. Perioperative SOX plus sintilimab vs P-SOX and CAPOX in advanced gastric cancer: A real-world comparison. World J Gastroenterol 2026; 32(29): 119809
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i29/119809.htm |
| DOI |
https://doi.org/10.3748/wjg.119809 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
